Pride @ Novartis 2020 – inspired to make a difference

We each have a story to tell.  A community that contributes to who we are today.  Heroes who hold us up in the face of challenges.

Our stories are what make us exceptional – they inspire those around us but also future generations.  At Novartis, we want to build an inclusive environment that values each of our unique stories, because it’s our differences that enable our global impact.  Our shared stories offer new ways of seeing the world that can help us to reimagine medicine for people everywhere.

…

/by

Novartis provides update on FDA review of ofatumumab, a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis

Basel, June 2, 2020 —  Novartis today announced that it has received notice from the US Food and Drug Administration (FDA) that the agency has extended its review of the Supplemental Biologics License Application (sBLA) for ofatumumab (OMB 157), a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis. Regulatory action is now expected in September 2020.

“Novartis will continue to work with the FDA to complete the review as soon as possible,” said Marie-France Tschudin, President, Novartis Pharmaceuticals. “We are well prepared …

/by

European Patient Innovation Summit publishes call for action to ensure greater patient involvement in digital health solution development

A new ‘Call to Action’ has been published by the European Patient Innovation Summit (EPIS) Steering Committee, calling for multiple stakeholders to ensure patients have a voice in the future of digital health solution development.

It will take the united efforts of all stakeholders to ensure the patient voice is stronger in digital health solution development,

Patrick Little, European Migraine & Headache Alliance (EMHA), Ireland

The new call to action challenges all parties involved in the …

/by